Association of cystatin C with heart failure with preserved ejection fraction in elderly hypertensive patients: Potential role of altered collagen metabolism

Journal of Hypertension

Volumn 34, Issue 1, 2016, Pages 130-138

  Huerta, Ana ^a   López, Begoña ^b,c   Ravassa, Susana ^b,c   José, Gorka San ^b,c   Querejeta, Ramón ^d   Beloqui, Óscar ^a,c   Zubillaga, Elena ^d   Rábago, Gregorio ^a,c   Brugnolaro, Cristina ^b   Díez, Javier ^a,b,c   González, Arantxa ^b,c  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

^c IdiSNA Navarra Institute for Health Research   (Spain)

^d HOSPITAL DONOSTIA   (Spain)

Author keywords

cystatin C; heart failure; myocardial fibrosis; osteopontin; preserved ejection fraction; tissue inhibitor of matrix metalloproteinases 1

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CARBOXY TERMINAL TELOPEPTIDE; CYSTATIN C; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLUCOSE; INTERSTITIAL COLLAGENASE; OSTEOPONTIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; BIOLOGICAL MARKER; COLLAGEN TYPE 1; MMP1 PROTEIN, HUMAN; PEPTIDE FRAGMENT; PROCOLLAGEN; PROCOLLAGEN TYPE I CARBOXY TERMINAL PEPTIDE; TIMP1 PROTEIN, HUMAN;

AGED; ARTICLE; COLLAGEN METABOLISM; COLLAGEN SYNTHESIS; CONTROLLED STUDY; DIASTOLIC DYSFUNCTION; DISEASE ASSOCIATION; ECHOCARDIOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; GLOMERULUS FILTRATION RATE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART FIBROBLAST; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HUMAN CELL; HYPERTENSION; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULMONARY ARTERY OCCLUSION PRESSURE; BLOOD; CARDIAC MUSCLE; CASE CONTROL STUDY; CELL CULTURE; COMPLICATION; CYTOLOGY; DRUG EFFECTS; ECHOGRAPHY; FIBROBLAST; FIBROSIS; HEART FAILURE; HEART STROKE VOLUME; LUNG WEDGE PRESSURE; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY;

AGED; BIOMARKERS; CASE-CONTROL STUDIES; CELLS, CULTURED; COLLAGEN TYPE I; CYSTATIN C; ECHOCARDIOGRAPHY; FEMALE; FIBROBLASTS; FIBROSIS; GLOMERULAR FILTRATION RATE; HEART FAILURE; HUMANS; HYPERTENSION; MALE; MATRIX METALLOPROTEINASE 1; MIDDLE AGED; MYOCARDIUM; OSTEOPONTIN; PEPTIDE FRAGMENTS; PROCOLLAGEN; PULMONARY WEDGE PRESSURE; STROKE VOLUME; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 84951568421     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000000757     Document Type: Article

References (36)

1. Borlaug BA, Paulus WJ. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur Heart J 2011; 32:670-679.
2. Westermann D, Kasner M, Steendijk P, Spillmann F, Riad A, Weitmann K, et al. Role of left ventricular stiffness in heart failure with normal ejection fraction. Circulation 2008; 117:2051-2060.
3. Querejeta R, López B, González A, Sánchez E, Larman M, Martínez Ubago JL, Díez J. Increased collagen type I synthesis in patients with heart failure of hypertensive origin: relation to myocardial fibrosis. Circulation 2004; 110:1263-1268.
4. González A, López B, Querejeta R, Zubillaga E, Echeverría T, Díez J. Filling pressures and collagen metabolism in hypertensive patients with heart failure and normal ejection fraction. Hypertension 2010; 55:1418-1424.
5. Madero M, Sarnak MJ, Stevens LA. Serum cystatin C as a marker of glomerular filtration rate. Curr Opin Nephrol Hypertens 2006; 15:610-616.
6. Xie L, Terrand J, Xu B, Tsaprailis G, Boyer J, Chen QM. Cystatin C increases in cardiac injury: a role in extracellular matrix protein modulation. Cardiovasc Res 2010; 87:628-635.
7. Cheng XW, Obata K, Kuzuya M, Izawa H, Nakamura K, Asai E, et al. Elastolytic cathepsin induction/activation system exists in myocardium and is upregulated in hypertensive heart failure. Hypertension 2006; 48:979-987.
8. Sarnak MJ, Katz R, Stehman-Breen CO, Fried LF, Jenny NS, Psaty BM, et al. Cystatin C concentration as a risk factor for heart failure in older adults. Ann Intern Med 2005; 142:497-505.
9. Patel PC, Ayers CR, Murphy SA, Peshock R, Khera A, de Lemos JA, et al. Association of cystatin C with left ventricular structure and function: the Dallas Heart Study. Circ Heart Fail 2009; 2:98-104.
10. Tang WH, Van Lente F, Shrestha K, Troughton RW, Francis GS, Tong W, et al. Impact of myocardial function on cystatin C measurements in chronic systolic heart failure. J Card Fail 2008; 14:394-399.
11. Shlipak MG, Katz R, Fried LF, Jenny NS, Stehman-Breen C, Newman AB, et al. Cystatin-C and mortality in elderly persons with heart failure. J Am Coll Cardiol 2005; 45:268-271.
12. Shah KS, Maisel AS. Novel biomarkers in heart failure with preserved ejection fraction. Heart Fail Clin 2014; 10:471-479.
13. Zahradka P. Novel role for osteopontin in cardiac fibrosis. Circ Res 2008; 102:270-272.
14. López B, González A, Lindner D, Westermann D, Ravassa S, Beaumont J, et al. Osteopontin-mediated myocardial fibrosis in heart failure: a role for lysyl oxidase? Cardiovasc Res 2013; 99:111-120.
15. López B, González A, Díez J. Circulating biomarkers of collagen metabolism in cardiac diseases. Circulation 2010; 121:1645-1654.
16. Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldman AM, Francis GS, et al. ACC/AHA Guidelines for the evaluation and management of chronic heart failure in the adult: Executive Summary and Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2001; 104:2996-3007.
17. Paulus WJ, Tschöpe C, Sandersen JE, Rusconi C, Flachskampf FA, Rademakers FE, et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 2007; 28:2539-2550.
18. Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16:31-41.
19. Quinones MA, Pickering E, Alexander JK. Percentage of shortening of the echocardiographic left ventricular dimension: its use in determining ejection fraction and stroke volume. Chest 1978; 4:59-65.
20. de Simone G, Devereux RB, Roman MJ, Ganau A, Saba PS, Alderman MH, Laragh JH. Assessment of left ventricular function by the midwall fractional shortening/end-systolic stress relation in human hypertension. J Am Coll Cardiol 1994; 23:1444-1451.
21. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantification. Eur J Echocardiogr 2006; 7:79-108.
22. Nagueh SF, Middleton KJ, Kopelen HA, Zoghbi WA, Quiñones MA. Doppler tissue imaging: a noninvasive technique for evaluation of left ventricular relaxation and estimation of filling pressures. J Am Coll Cardiol 1997; 30:1527-1533.
23. López B, González A, Querejeta R, Larman M, Rábago G, Díez J. Association of cardiotrophin-1 with myocardial fibrosis in hypertensive patients with heart failure. Hypertension 2014; 63:483-489.
24. Pepine CJ. Pressure measurement and determination of vascular resistance. In: Pepine CJ, Hill JA, Lambert CR, editors. Diagnostic and therapeutic cardiac catheterization, 3rd ed. Baltimore, MD: Lippincott, Williams and Wilkins; 1998. pp. 442-458.
25. Cleland JG, Pellicori P, Dierckx R. Clinical trials in patients with heart failure and preserved left ventricular ejection fraction. Heart Fail Clin 2014; 10:511-523.
26. Gori M, Senni M, Gupta DK, Charytan DM, Kraigher-Krainer E, Pieske B, et al. Association between renal function and cardiovascular structure and function in heart failure with preserved ejection fraction. Eur Heart J 2014; 35:3442-3451.
27. Djoussé L, Kurth T, Gaziano JM. Cystatin C and risk of heart failure in the Physicians' Health Study (PHS). Am Heart J 2008; 155:82-86.
28. Nosaka K, Nakamura K, Kusano K, Toh N, Tada T, Miyoshi T, et al. Serum cystatin C as a biomarker of cardiac diastolic dysfunction in patients with cardiac disease and preserved ejection fraction. Congest Heart Fail 2013; 19:E35-E39.
29. Ix JH, Shlipak MG, Chertow GM, Ali S, Schiller NB, Whooley MA, Cystatin C. left ventricular hypertrophy, and diastolic dysfunction: data from the Heart and Soul Study. J Card Fail 2006; 12:601-607.
30. Shlipak MG, Katz R, Sarnak MJ, Fried LF, Newman AB, Stehman-Breen C, et al. Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med 2006; 145:237-246.
31. Díez J. Emerging role of matrix metalloproteinases in the pathophysiology of cardiac diseases. Eur J Clin Inves 2002; 32:291-294.
32. Cheng XW, Shi GP, Kuzuya M, Sasaki T, Okumura K, Murohara T. Role for cysteine protease cathepsins in heart disease: focus on biology and mechanisms with clinical implication. Circulation 2012; 125:1551-1562.
33. Kasabova M, Joulin-Giet A, Lecaille F, Gilmore BF, Marchand-Adam S, Saidi A, Lalmanach G. Regulation of TGF-b1-driven differentiation of human lung fibroblasts: emerging roles of cathepsin B and cystatin C. J Biol Chem 2014; 289:16239-16251.
34. Murphy N, Lynch MA. Activation of the P2X7 receptor induces migration of glial cells by inducing cathepsin B degradation of tissue inhibitor of metalloproteinase 1. J Neurochem 2012; 123:761-770.
35. Takeuchi M, Fukuda Y, Nakano I, Katano Y, Hayakawa T. Elevation of serum cystatin C concentrations in patients with chronic liver disease. Eur J Gastroenterol Hepatol 2001; 13:951-955.
36. Xu Y, Ding Y, Li X, Wu X. Cystatin C is a disease-associated protein subject to multiple regulation. Immunol Cell Biol 2015; 93:442-451.